Qualcomm Agrees to $75M Settlement Over Licensing Practicesby Mark Eisenberg 19.06.2024Qualcomm settles for $75M with shareholders over hidden sales practices; awaits judge's approval. Significant impact on investor trust and market ...
3 EV Stocks to Invest In for Potential Richesby Mark Eisenberg 18.06.2024Explore why electric vehicles like Tesla, GM, and Albemarle are poised to bring investors from rags to riches amid evolving ...
Alignment Healthcare Director Sells Shares, Ups Price Targetby Mark Eisenberg 18.06.2024"Jeffrey H. Margolis of Alignment Healthcare sells 1,200 shares worth $9,672. Despite insider sale, company sees 50% membership increase."
International Seaways Exec Sells $414K in Stock Amid Q1 Gainsby Mark Eisenberg 18.06.2024"James D. Small III, CAO of International Seaways, sells $414k in stock amid company's robust Q1 2024 performance. Investors take ...
Chipotle Announces Historic 50-for-1 Stock Splitby Mark Eisenberg 18.06.2024Historic Chipotle 50-for-1 stock split: Hold shares by June 18 to benefit. Split aims to make stock accessible; trading on ...
Ethereum’s Top Exchange Wallets Hit 6-Year Lowby John Darbie 18.06.2024"Top 100 Ethereum exchange wallets hit a 6-year low, while non-exchange wallets soar, reflecting a shift towards staking and DeFi. ...
Sacks Parente Golf Director Purchases 30,833 Sharesby Mark Eisenberg 18.06.2024Sacks Parente Golf sees confidence boost as Director Brett Widney invests $15K, highlighting growth potential despite past stock volatility.
Piper Sandler Reaffirms Ellington With $13 Targetby Mark Eisenberg 18.06.2024"Piper Sandler reaffirms Ellington Financial as 'Overweight' with a $13 price target, citing strategic acquisitions and robust earnings outlook."
Top Stocks to Watch: Best Buy, GameStop, Micron Analysisby Mark Eisenberg 18.06.2024Discover why Best Buy, GameStop, and Micron Technology are stocks to watch this week with upgrades, shareholder buzz, and strong ...
Roche’s Hemlibra Battles Fierce Competition Amid Rating Holdby Mark Eisenberg 17.06.2024Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...